Astrazeneca says Catalent deal shows need for in-house capacity
Published
The sale of listed contract drugmaker Catalent to the parent of Novo Nordisk this week demonstrates the importance for big pharma companies of building an independent supply chain, Astrazeneca said Thursday. AstraZeneca, which is a client of Catalent for some of its drug manufacturing, is working…
#catalent #novonordisk #astrazeneca #pascalsoriot #maryland #novoholdings #novo #elililly